Academe Learn
CBME Curriculum Preview

Page 26 of 26

PE18.1-14 | Immunization — PBL Case

CLINICAL SETTING

Rampura village, Barmer district, Rajasthan. Population: ~1,200. The nearest Primary Health Centre (PHC) is 14 km away. A field-level health worker (ASHA) reports 4 children aged 9 months to 4 years with fever, cough, coryza, conjunctivitis, and rash within the past 10 days — a suspected measles cluster. The district immunization officer has requested a paediatric team to investigate and respond. You are the paediatric medical officer joining the rapid response team.

Trigger 1: The Cluster

On arrival, you review the MCP cards of the 4 affected children: - Child 1: 9-month-old girl — BCG, OPV-0, and Pentavalent-1/OPV-1 given; no further vaccines. - Child 2: 2-year-old boy — BCG, full primary series, DPT booster given at 18 months; MR-1 NOT given; MR-2 NOT given. - Child 3: 11-month-old boy — BCG, full primary series, OPV-3; no MR-1 (mother said 'no rash from vaccine needed'). - Child 4: 4-year-old girl — all vaccines up to DPT booster at 18 months; MR-1 given at 9 months; MR-2 not given. All four children have Koplik's spots on Day 2–3 of illness, and a descending maculopapular rash beginning from the face. You confirm clinical measles in all four.

DISCUSSION POINTS

  • What is the rationale for giving two doses of MR vaccine in the NIS, and why has Child 4 (who received MR-1) still developed measles?
  • Which of the four children represents a vaccine failure versus a vaccine programme gap? How does this affect your response strategy?
  • What is the case definition of a vaccine-preventable disease cluster, and when is an outbreak declared?
Click to reveal Trigger 2: Cold Chain Failure Discovered (discuss previous trigger first!)

Trigger 2: Cold Chain Failure Discovered

The ASHA accompanies you to the subcentre and opens the vaccine carrier. You notice: - OPV vials: VVM Stage 3 (inner square matches outer circle) - Pentavalent vials: stored in the vaccine carrier; when shaken vigorously for 10 seconds and left to stand for 30 minutes, a compact white sediment forms that does not redisperse. - BCG powder (lyophilized) in the vaccine carrier: no VVM change observed. The ASHA mentions that last week, ice packs were not replaced in the carrier for an entire session because the PHC deep freezer malfunctioned. The district cold chain officer confirms the deep freezer was at −5°C (not −20°C) for 48 hours before being repaired.

DISCUSSION POINTS

  • Which vaccines from this carrier are safe to use, and which must be quarantined or discarded? Justify each decision.
  • What are the specific temperature requirements for the deep freezer and ILR at the PHC level? What is the consequence of −5°C for 48 hours on OPV and pentavalent?
  • What corrective steps should the cold chain officer take immediately, and what documentation is required for a cold chain failure report?
  • How should the ASHA be counselled regarding the consequences of not replacing ice packs during outreach sessions?
Click to reveal Trigger 3: A Hesitant Mother and a Special Child (discuss previous trigger first!)

Trigger 3: A Hesitant Mother and a Special Child

During the door-to-door survey, you identify a 13-month-old boy (Salim) who has not received any vaccines after OPV-0 and Hepatitis B birth dose. His mother is hesitant: 'My neighbour's child got fever and fits after a vaccine.' A review of Salim's records reveals he was born HIV-exposed (mother is HIV-positive on ART; Salim's HIV DNA PCR at 6 weeks was negative). His last HIV DNA PCR at 12 months was also negative. He weighs 9 kg (normal for age) and is clinically well. A second child in the same household — a 5-year-old girl (Priya) — received her DPT booster 6 months ago but had an episode of hypotonic-hyporesponsiveness (HHE) lasting 4 hours within 24 hours of the injection, which resolved spontaneously.

DISCUSSION POINTS

  • What is the vaccination plan for Salim — an HIV-exposed, PCR-negative, currently healthy 13-month-old? Which vaccines should be given, and which require special consideration?
  • How would you counsel Salim's mother, addressing her specific fear about 'fits after vaccines'? What is the AEFI classification of the neighbour child's event, and how does this change your counselling?
  • For Priya, HHE after DPT is a precaution, not an absolute contraindication. What is the recommended approach for her future pertussis-containing vaccines?
  • What ethical and legal considerations apply when a parent refuses vaccination for an HIV-exposed child in the context of a measles outbreak?
Click to reveal Trigger 4: Outbreak Response and Newer Vaccines (discuss previous trigger first!)

Trigger 4: Outbreak Response and Newer Vaccines

The district immunization officer confirms a measles outbreak and launches a mass immunization campaign (MIC). The district medical officer asks you to review which newer vaccines, beyond the UIP schedule, would have reduced this outbreak's severity or prevented secondary complications in this population. Additionally, a 16-year-old girl in the village asks about the 'cervical cancer vaccine' she heard about at school. A 60-year-old woman accompanying her grandson asks whether a typhoid vaccine is available for the children in the family.

DISCUSSION POINTS

  • Which newer vaccines available in India — including those recently added or being expanded under UIP — could have reduced the outbreak burden? Include rotavirus, PCV, JE, and HPV in your discussion.
  • What is the target age range and schedule for HPV vaccine in India's national programme? Explain the rationale for the age of first dose (9–14 years) in girls.
  • What is the role of mass immunization campaigns vs routine immunization in measles control? What is 'herd immunity threshold' for measles, and what coverage is required?
  • For the 60-year-old woman's grandchildren, is typhoid vaccine part of UIP? What is the current status of typhoid conjugate vaccine (TCV) in India?

Group Task Assignments

Group 1: Collaborative Task

Group 2: Collaborative Task

Group 3: Collaborative Task

Learning Issues

Research these questions and bring your findings to the discussion.

  1. [PE18.1] What are the components of the UIP and the difference between scheduled vaccines and supplemental immunization activities (SIAs)?
  2. [PE18.2] What is the disease burden of measles in India — incidence, mortality, and complications — and how does vaccination coverage affect outbreak risk?
  3. [PE18.3] What are the storage conditions, dose, route, schedule, and contraindications for MR vaccine, OPV, pentavalent, and BCG?
  4. [PE18.4] What are the cold chain requirements at each level of the immunization system, and what is the procedure for managing a cold chain failure?
  5. [PE18.5] How are vaccination decisions modified in HIV-exposed/positive children, preterm infants, and children with prior AEFI?
  6. [PE18.6] How do you construct a catch-up immunization schedule for a child with incomplete or delayed vaccination?
  7. [PE18.7] What are the key evidence-based communication strategies to address vaccine hesitancy in Indian rural communities?
  8. [PE18.8] How are AEFIs classified using the WHO 2013 criteria, and what is the reporting pathway for serious versus non-serious AEFIs?
  9. [PE18.13] What is implied consent in the context of immunization services, and what are the ethical obligations when a parent refuses vaccination during an outbreak?
  10. [PE18.14] Which newer vaccines (PCV, rotavirus, JE, HPV, TCV) are available or being expanded under UIP in India, and what is the rationale for their inclusion?